Cover Image
市場調查報告書

全球免疫查核點抑制劑市場

Global Market Study on Immune Checkpoint Inhibitors: North America's Dominance in the Market will Remain Unchallenged during 2017 - 2026

出版商 Persistence Market Research 商品編碼 599107
出版日期 內容資訊 英文 170 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球免疫查核點抑制劑市場 Global Market Study on Immune Checkpoint Inhibitors: North America's Dominance in the Market will Remain Unchallenged during 2017 - 2026
出版日期: 2017年11月24日 內容資訊: 英文 170 Pages
簡介

本報告提供全球免疫查核點抑制劑市場相關調查,市場概要與成長預測,各地區,各類藥物,各流通管道趨勢,及打入市場的主要企業的簡介等彙整資料。

第1章 全球展望

第2章 摘要整理

第3章 市場概要

  • 簡介
  • 全球免疫查核點抑制劑市場規模與預測
  • 市場趨勢
  • 供應鏈
  • 大環境分析
  • 各地區市場定位評估
  • 波特五力分析
  • 開發平台評估
  • 償付支援方案
  • 主要參與企業的市場上地位

第4章 全球免疫查核點抑制劑市場分析與預測

  • 各類藥物市場規模與預測
  • 各流通管道市場規模與預測
  • 各治療用途市場規模與預測

第5章 北美市場

  • 市場預測
  • 醫藥品產業預測
  • 各國收益比較
  • 各類藥物收益比較
  • 各流通管道收益比較
  • 各治療用途收益比較

第6章 南美市場

第7章 歐洲市場

第8章 日本市場

第9章 亞太地區市場

第10章 中東、非洲市場

第11章 企業佔有率,競爭環境,企業簡介

  • 企業佔有率分析
  • 競爭環境
  • 企業簡介
    • AstraZeneca Plc.
    • Bristol-Myers Squibb Co.
    • Celldex Therapeutics Inc.
    • Roche Holding AG
    • Incyte Corporation
    • Merck & Co., Inc.
    • Merck KGaA
    • Pfizer Inc.
    • Sanofi
    • Novartis AG

第12章 PMR調查方法

第13章 免責聲明

目錄

Persistence Market Research (PMR) has published a yet another exclusive forecast analysis on the global immune checkpoint inhibitors market. The report, titled "Immune Checkpoint Inhibitors Market - Global Industry Analysis (2012-2016) and Forecast (2017-2026)", examines key aspects impacting expansion of the global Immune checkpoint inhibitors market, and offers in-depth insights on the market for the forecast period, 2017-2026. The report delivers information on latest trends influencing expansion of the market in the next ten years. Competitive landscape of the global Immune checkpoint inhibitors market has been explored extensively in the report, deriving baseline values regarding market size estimations by aggregating revenues of market players.

Report Structure

The report starts with a chapter on executive summary of global Immune checkpoint inhibitors market, which highlights key research findings, especially across drug class and regional segments. A snapshot of the market size estimations, along with the forecast evaluations has been provided in this chapter. The report also offers an overview of the market, including standard definition of "Immune checkpoint inhibitors" coupled with a brief introduction of the market on the basis of analytical assessment.

The report offers market size estimations & forecast in terms of key metrics including compounded annual growth rate, year-on-year growth rate, basis point share index, and absolute dollar opportunity. Moving further, the report studies dynamic expansion of the global Immune checkpoint inhibitors market. This chapter provides analysis on factors restraining or driving the worldwide adoption of Immune checkpoint inhibitors. Lucrative opportunities and key trends are compiled in this chapter for enabling market players in considering the untapped entities for expansion of their business in the immediate future.

Competition Landscape

Last chapters in the report offer knowledge about global immune checkpoint inhibitors market's competition landscape. In these chapters, the report delivers Information pertaining to the market players in terms of product overview, SWOT analysis, key developments, company overview, and key financials of the market players. Chapters on the market's competition landscape are considered to be an indispensable part of the report, which provide readers with access to a detailed knowledge base to help them understand the past and current standings of prominent industries that actively contribute to global immune checkpoint inhibitors market's expansion. These chapters of the report offer essential information about the way of players' strategy implementation through which they aim in increasing their global market presence.

Research Methodology

Analysts at PMR have developed a comprehensive research methodology to come up with credible insights on future of various markets. Immune checkpoint inhibitors is more likely an emerging development in treatment of cancers, and is witnessing applications in the global healthcare marketplace. For developing this report, accuracy of these forecast market evaluations are assured by infusing the qualitative information with the quantitative data. Inferences delivered in this report may enable developers of Immune checkpoint inhibitors for devising informed strategies. A wide range of primary as well as secondary research methodologies have been employed for developing these inferences. Opinions of key industry leaders are assessed for validating viewpoints of PMR's analysts. By availing this report, companies can easily take informed decisions regarding future market direction.

Table of Content

Chapter 1 Global Outlook

  • 1.1 Pharmaceutical Industry: Global Outlook

Chapter 2 Global Immune Checkpoint Inhibitors Market - Executive Summary

Chapter 3 Global Immune Checkpoint Inhibitors Market Overview

  • 3.1 Introduction
    • 3.1.1 Global Immune Checkpoint Inhibitors Market Taxonomy
    • 3.1.2 Global Immune Checkpoint Inhibitors Market Definition
  • 3.2 Global Immune Checkpoint Inhibitors Market Size (US$ Mn) and Forecast, 2012-2026
    • 3.2.1 Global Immune Checkpoint Inhibitors Market Y-o-Y Growth
  • 3.3 Global Immune Checkpoint Inhibitors Market Dynamics
  • 3.4 Supply Chain
  • 3.5 PESTLE Analysis
  • 3.6 Regionwise Market Positioning Assessment
  • 3.7 Porter's Five Forces Analysis
  • 3.8 Pipeline Assessment
    • 3.8.1 AstraZeneca Plc.
    • 3.8.2 Bristol-Myers Squib
    • 3.8.3 Celldex Therapeutics Inc.
    • 3.8.4 Roche Holdings AG
    • 3.8.5 Merck & Co., Inc.
    • 3.8.6 Merck KgaA & Pfizer Inc.
    • 3.8.7 Sanofi
  • 3.9 Reimbursement Support Scenario
    • 3.9.1 OPDIVO® (nivolumab) & YERVOY® (ipilimumab)
    • 3.9.2 Tecentriq
    • 3.9.3 KEYTRUDA (pembrolizumab)
  • 3.10 Key Participants Market Presence (Intensity Map) By Region

Chapter 4 Global Immune Checkpoint Inhibitors Market Analysis and Forecast 2012-2026

  • 4.1 Global Immune Checkpoint Inhibitors Market Size and Forecast by Drug Class, 2012-2026
    • 4.1.1 PD-1 Market Size and Forecast, 2012-2026
      • 4.1.1.1 Revenue (US$ Mn) Comparison, By Region
      • 4.1.1.2 Market Share Comparison, By Region
      • 4.1.1.3 Y-o-Y growth Comparison, By Region
    • 4.1.2 PD-L1 Market Size and Forecast, 2012-2026
      • 4.1.2.1 Revenue (US$ Mn) Comparison, By Region
      • 4.1.2.2 Market Share Comparison, By Region
      • 4.1.2.3 Y-o-Y growth Comparison, By Region
    • 4.1.3 CTLA-4 Market Size and Forecast, 2012-2026
      • 4.1.3.1 Revenue (US$ Mn) Comparison, By Region
      • 4.1.3.2 Market Share Comparison, By Region
      • 4.1.3.3 Y-o-Y growth Comparison, By Region
  • 4.2 Global Immune Checkpoint Inhibitors Market Size and Forecast by Distribution Channel, 2012-2026
    • 4.2.1 Hospital Pharmacies Market Size and Forecast, 2012-2026
      • 4.2.1.1 Revenue (US$ Mn) Comparison, By Region
      • 4.2.1.2 Market Share Comparison, By Region
      • 4.2.1.3 Y-o-Y growth Comparison, By Region
    • 4.2.2 Retail Pharmacies Market Size and Forecast, 2012-2026
      • 4.2.2.1 Revenue (US$ Mn) Comparison, By Region
      • 4.2.2.2 Market Share Comparison, By Region
      • 4.2.2.3 Y-o-Y growth Comparison, By Region
    • 4.2.3 Specialty Pharmacies Market Size and Forecast, 2012-2026
      • 4.2.3.1 Revenue (US$ Mn) Comparison, By Region
      • 4.2.3.2 Market Share Comparison, By Region
      • 4.2.3.3 Y-o-Y growth Comparison, By Region
  • 4.3 Global Immune Checkpoint Inhibitors Market Size and Forecast by Therapeutic Application, 2012-2026
    • 4.3.1 Melanoma Market Size and Forecast, 2012-2026
      • 4.3.1.1 Revenue (US$ Mn) Comparison, By Region
      • 4.3.1.2 Market Share Comparison, By Region
      • 4.3.1.3 Y-o-Y growth Comparison, By Region
    • 4.3.2 Lung Cancer Market Size and Forecast, 2012-2026
      • 4.3.2.1 Revenue (US$ Mn) Comparison, By Region
      • 4.3.2.2 Market Share Comparison, By Region
      • 4.3.2.3 Y-o-Y growth Comparison, By Region
    • 4.3.3 Blood Cancers Market Size and Forecast, 2012-2026
      • 4.3.3.1 Revenue (US$ Mn) Comparison, By Region
      • 4.3.3.2 Market Share Comparison, By Region
      • 4.3.3.3 Y-o-Y growth Comparison, By Region
    • 4.3.4 Renal Cell Carcinoma Market Size and Forecast, 2012-2026
      • 4.3.4.1 Revenue (US$ Mn) Comparison, By Region
      • 4.3.4.2 Market Share Comparison, By Region
      • 4.3.4.3 Y-o-Y growth Comparison, By Region
    • 4.3.5 Squamous Cell Carcinoma Market Size and Forecast, 2012-2026
      • 4.3.5.1 Revenue (US$ Mn) Comparison, By Region
      • 4.3.5.2 Market Share Comparison, By Region
      • 4.3.5.3 Y-o-Y growth Comparison, By Region
    • 4.3.6 Urothelial Carcinoma Market Size and Forecast, 2012-2026
      • 4.3.6.1 Revenue (US$ Mn) Comparison, By Region
      • 4.3.6.2 Market Share Comparison, By Region
      • 4.3.6.3 Y-o-Y growth Comparison, By Region
    • 4.3.7 Colorectal Cancer Market Size and Forecast, 2012-2026
      • 4.3.7.1 Revenue (US$ Mn) Comparison, By Region
      • 4.3.7.2 Market Share Comparison, By Region
      • 4.3.7.3 Y-o-Y growth Comparison, By Region
    • 4.3.8 Other Cancers Market Size and Forecast, 2012-2026
      • 4.3.8.1 Revenue (US$ Mn) Comparison, By Region
      • 4.3.8.2 Market Share Comparison, By Region
      • 4.3.8.3 Y-o-Y growth Comparison, By Region

Chapter 5 North America Immune Checkpoint Inhibitors Market Size and Forecast, 2012-2026

  • 5.1 North America Market Outlook
  • 5.2 North America Pharmaceutical Industry Outlook
  • 5.3 Revenue (US$ Mn) Comparison, By Country
  • 5.4 Revenue (US$ Mn) Comparison, By Drug Class
  • 5.5 Revenue (US$ Mn) Comparison, By Distribution Channel
  • 5.6 Revenue (US$ Mn) Comparison, By Therapeutic Application

Chapter 6 Latin America Immune Checkpoint Inhibitors Market Size and Forecast, 2012-2026

  • 6.1 Latin America Market Outlook
  • 6.2 Latin America Pharmaceutical Industry Outlook
  • 6.3 Revenue (US$ Mn) Comparison, By Country
  • 6.4 Revenue (US$ Mn) Comparison, By Drug Class
  • 6.5 Revenue (US$ Mn) Comparison, By Distribution Channel
  • 6.6 Revenue (US$ Mn) Comparison, By Therapeutic Application

Chapter 7 Europe Immune Checkpoint Inhibitors Market Size and Forecast, 2012-2026

  • 7.1 Europe Market Outlook
  • 7.2 Europe Pharmaceutical Industry Outlook
  • 7.3 Revenue (US$ Mn) Comparison, By Country
  • 7.4 Revenue (US$ Mn) Comparison, By Drug Class
  • 7.5 Revenue (US$ Mn) Comparison, By Distribution Channel
  • 7.6 Revenue (US$ Mn) Comparison, By Therapeutic Application

Chapter 8 Japan Immune Checkpoint Inhibitors Market Size and Forecast, 2012-2026

  • 8.1 Japan Market Outlook
  • 8.2 Japan Pharmaceutical Industry Outlook
  • 8.3 Revenue (US$ Mn) Comparison, By Country
  • 8.4 Revenue (US$ Mn) Comparison, By Drug Class
  • 8.5 Revenue (US$ Mn) Comparison, By Distribution Channel
  • 8.6 Revenue (US$ Mn) Comparison, By Therapeutic Application

Chapter 9 APEJ Immune Checkpoint Inhibitors Market Size and Forecast, 2012-2026

  • 9.1 APEJ Market Outlook
  • 9.2 APEJ Pharmaceutical Industry Outlook
  • 9.3 Revenue (US$ Mn) Comparison, By Country
  • 9.4 Revenue (US$ Mn) Comparison, By Drug Class
  • 9.5 Revenue (US$ Mn) Comparison, By Distribution Channel
  • 9.6 Revenue (US$ Mn) Comparison, By Therapeutic Application

Chapter 10 MEA Immune Checkpoint Inhibitors Market Size and Forecast, 2012-2026

  • 10.1 MEA Market Outlook
  • 10.2 MEA Pharmaceutical Industry Outlook
  • 10.3 Revenue (US$ Mn) Comparison, By Country
  • 10.4 Revenue (US$ Mn) Comparison, By Drug Class
  • 10.5 Revenue (US$ Mn) Comparison, By Distribution Channel
  • 10.6 Revenue (US$ Mn) Comparison, By Therapeutic Application

Chapter 11 Global Immune Checkpoint Inhibitors Market Company Share, Competition Landscape and Company Profiles

  • 11.1 Global Immune Checkpoint Inhibitors Market - Company Share Analysis
  • 11.2 Global Immune Checkpoint Inhibitors Market - Competitive Landscape
  • 11.3 Global Immune Checkpoint Inhibitors Market - Company Profile
    • 11.3.1 AstraZeneca Plc.
      • 11.3.1.1 Company Overview
      • 11.3.1.2 Product Overview
      • 11.3.1.3 Key Financials
      • 11.3.1.4 Key Developments
      • 11.3.1.5 SWOT Analysis
    • 11.3.2 Bristol-Myers Squibb Co.
      • 11.3.2.1 Company Overview
      • 11.3.2.2 Product Overview
      • 11.3.2.3 Key Financials
      • 11.3.2.4 Key Developments
      • 11.3.2.5 SWOT Analysis
    • 11.3.3 Celldex Therapeutics Inc.
      • 11.3.3.1 Company Overview
      • 11.3.3.2 Product Overview
      • 11.3.3.3 Key Financials
      • 11.3.3.4 Key Developments
      • 11.3.3.5 SWOT Analysis
    • 11.3.4 Roche Holding AG
      • 11.3.4.1 Company Overview
      • 11.3.4.2 Product Overview
      • 11.3.4.3 Key Financials
      • 11.3.4.4 Key Developments
      • 11.3.4.5 SWOT Analysis
    • 11.3.5 Incyte Corporation
      • 11.3.5.1 Company Overview
      • 11.3.5.2 Product Overview
      • 11.3.5.3 Key Financials
      • 11.3.5.4 Key Developments
    • 11.3.6 Merck & Co., Inc.
      • 11.3.6.1 Company Overview
      • 11.3.6.2 Product Overview
      • 11.3.6.3 Key Financials
      • 11.3.6.4 Key Developments
      • 11.3.6.5 SWOT Analysis
    • 11.3.7 Merck KGaA
      • 11.3.7.1 Company Overview
      • 11.3.7.2 Product Overview
      • 11.3.7.3 Key Financials
      • 11.3.7.4 Key Developments
      • 11.3.7.5 SWOT Analysis
    • 11.3.8 Pfizer Inc.
      • 11.3.8.1 Company Overview
      • 11.3.8.2 Product Overview
      • 11.3.8.3 Key Financials
      • 11.3.8.4 Key Developments
      • 11.3.8.5 SWOT Analysis
    • 11.3.9 Sanofi
      • 11.3.9.1 Company Overview
      • 11.3.9.2 Product Overview
      • 11.3.9.3 Key Financials
      • 11.3.9.4 Key Developments
      • 11.3.9.5 SWOT Analysis
    • 11.3.10 Novartis AG
      • 11.3.10.1 Company Overview
      • 11.3.10.2 Product Overview
      • 11.3.10.3 Key Financials
      • 11.3.10.4 Key Developments
      • 11.3.10.5 SWOT Analysis

Chapter 12 PMR Research Methodology

Chapter 13 Disclaimer

List of Tables

TABLE 1 Global Immune Checkpoint Inhibitors Market Value (US$ Mn), 2012-2017

TABLE 2 Global Immune Checkpoint Inhibitors Market Value (US$ Mn), 2018-2026

TABLE 3 Global Immune Checkpoint Inhibitors Market Value (US$ Mn) and Y-o-Y, 2017-2026

TABLE 4 Global PD-1 Segment Value (US$ Mn), By Region 2012-2017

TABLE 5 Global PD-1 Segment Value (US$ Mn), By Region 2018-2026

TABLE 6 Global PD-1 Segment Market Share, By Region 2012-2017

TABLE 7 Global PD-1 Segment Market Share, By Region 2018-2026

TABLE 8 Global PD-1 Segment Y-o-Y, By Region 2017-2026

TABLE 9 Global PD-L1 Segment Value (US$ Mn), By Region 2012-2017

TABLE 10 Global PD-L1 Segment Value (US$ Mn), By Region 2018-2026

TABLE 11 Global PD-L1 Segment Market Share, By Region 2012-2017

TABLE 12 Global PD-L1 Segment Market Share, By Region 2018-2026

TABLE 13 Global PD-L1 Segment Y-o-Y, By Region 2017-2026

TABLE 14 Global CTLA-4 Segment Value (US$ Mn), By Region 2012-2017

TABLE 15 Global CTLA-4 Segment Value (US$ Mn), By Region 2018-2026

TABLE 16 Global CTLA-4 Segment Market Share, By Region 2012-2017

TABLE 17 Global CTLA-4 Segment Market Share, By Region 2018-2026

TABLE 18 Global CTLA-4 Segment Y-o-Y, By Region 2017-2026

TABLE 19 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2012-2017

TABLE 20 Global Hospital Pharmacies Segment Value (US$ Mn), By Region 2018-2026

TABLE 21 Global Hospital Pharmacies Segment Market Share, By Region 2012-2017

TABLE 22 Global Hospital Pharmacies Segment Market Share, By Region 2018-2026

TABLE 23 Global Hospital Pharmacies Segment Y-o-Y, By Region 2017-2026

TABLE 24 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2012-2017

TABLE 25 Global Retail Pharmacies Segment Value (US$ Mn), By Region 2018-2026

TABLE 26 Global Retail Pharmacies Segment Market Share, By Region 2012-2017

TABLE 27 Global Retail Pharmacies Segment Market Share, By Region 2018-2026

TABLE 28 Global Retail Pharmacies Segment Y-o-Y, By Region 2017-2026

TABLE 29 Global Specialty Pharmacies Segment Value (US$ Mn), By Region 2012-2017

TABLE 30 Global Specialty Pharmacies Segment Value (US$ Mn), By Region 2018-2026

TABLE 31 Global Specialty Pharmacies Segment Market Share, By Region 2012-2017

TABLE 32 Global Specialty Pharmacies Segment Market Share, By Region 2018-2026

TABLE 33 Global Specialty Pharmacies Segment Y-o-Y, By Region 2017-2026

TABLE 34 Global Melanoma Segment Value (US$ Mn), By Region 2012-2017

TABLE 35 Global Melanoma Segment Value (US$ Mn), By Region 2018-2026

TABLE 36 Global Melanoma Segment Market Share, By Region 2012-2017

TABLE 37 Global Melanoma Segment Market Share, By Region 2018-2026

TABLE 38 Global Melanoma Segment Y-o-Y, By Region 2017-2026

TABLE 39 Global Lung Cancer Segment Value (US$ Mn), By Region 2012-2017

TABLE 40 Global Lung Cancer Segment Value (US$ Mn), By Region 2018-2026

TABLE 41 Global Lung Cancer Segment Market Share, By Region 2012-2017

TABLE 42 Global Lung Cancer Segment Market Share, By Region 2018-2026

TABLE 43 Global Lung Cancer Segment Y-o-Y, By Region 2017-2026

TABLE 44 Global Blood Cancers Segment Value (US$ Mn), By Region 2012-2017

TABLE 45 Global Blood Cancers Segment Value (US$ Mn), By Region 2018-2026

TABLE 46 Global Blood Cancers Segment Market Share, By Region 2012-2017

TABLE 47 Global Blood Cancers Segment Market Share, By Region 2018-2026

TABLE 48 Global Blood Cancers Segment Y-o-Y, By Region 2017-2026

TABLE 49 Global Renal Cell Carcinoma Segment Value (US$ Mn), By Region 2012-2017

TABLE 50 Global Renal Cell Carcinoma Segment Value (US$ Mn), By Region 2018-2026

TABLE 51 Global Renal Cell Carcinoma Segment Market Share, By Region 2012-2017

TABLE 52 Global Renal Cell Carcinoma Segment Market Share, By Region 2018-2026

TABLE 53 Global Renal Cell Carcinoma Segment Y-o-Y, By Region 2017-2026

TABLE 54 Global Squamous Cell Carcinoma Segment Value (US$ Mn), By Region 2012-2017

TABLE 55 Global Squamous Cell Carcinoma Segment Value (US$ Mn), By Region 2018-2026

TABLE 56 Global Squamous Cell Carcinoma Segment Market Share, By Region 2012-2017

TABLE 57 Global Squamous Cell Carcinoma Segment Market Share, By Region 2018-2026

TABLE 58 Global Squamous Cell Carcinoma Segment Y-o-Y, By Region 2017-2026

TABLE 59 Global Urothelial Carcinoma Segment Value (US$ Mn), By Region 2012-2017

TABLE 60 Global Urothelial Carcinoma Segment Value (US$ Mn), By Region 2018-2026

TABLE 61 Global Urothelial Carcinoma Segment Market Share, By Region 2012-2017

TABLE 62 Global Urothelial Carcinoma Segment Market Share, By Region 2018-2026

TABLE 63 Global Urothelial Carcinoma Segment Y-o-Y, By Region 2017-2026

TABLE 64 Global Colorectal Cancer Segment Value (US$ Mn), By Region 2012-2017

TABLE 65 Global Colorectal Cancer Segment Value (US$ Mn), By Region 2018-2026

TABLE 66 Global Colorectal Cancer Segment Market Share, By Region 2012-2017

TABLE 67 Global Colorectal Cancer Segment Market Share, By Region 2018-2026

TABLE 68 Global Colorectal Cancer Segment Y-o-Y, By Region 2017-2026

TABLE 69 Global Other Cancers Segment Value (US$ Mn), By Region 2012-2017

TABLE 70 Global Other Cancers Segment Value (US$ Mn), By Region 2018-2026

TABLE 71 Global Other Cancers Segment Market Share, By Region 2012-2017

TABLE 72 Global Other Cancers Segment Market Share, By Region 2018-2026

TABLE 73 Global Other Cancers Segment Y-o-Y, By Region 2017-2026

TABLE 74 North America Current Expenditure on Health, (% of GDP), by Country, 2010 - 2016

TABLE 75 North America Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016

TABLE 76 North America Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016

TABLE 77 North America Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016

TABLE 78 North America Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016

TABLE 79 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017

TABLE 80 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026

TABLE 81 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017

TABLE 82 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026

TABLE 83 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017

TABLE 84 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026

TABLE 85 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017

TABLE 86 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026

TABLE 87 Latin America Current Expenditure on Health, (% of GDP), by Country, 2010 - 2016

TABLE 88 Latin America Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016

TABLE 89 Latin America Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016

TABLE 90 Latin America Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016

TABLE 91 Latin America Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016

TABLE 92 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017

TABLE 93 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026

TABLE 94 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017

TABLE 95 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026

TABLE 96 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017

TABLE 97 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026

TABLE 98 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017

TABLE 99 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026

TABLE 100 Europe Current Expenditure on Health, (% of GDP), by Country, 2010 - 2016

TABLE 101 Europe Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016

TABLE 102 Europe Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016

TABLE 103 Europe Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016

TABLE 104 Europe Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016

TABLE 105 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017

TABLE 106 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026

TABLE 107 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017

TABLE 108 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026

TABLE 109 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017

TABLE 110 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026

TABLE 111 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017

TABLE 112 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026

TABLE 113 Japan Current Expenditure on Health, (% of GDP), by Country, 2010 - 2016

TABLE 114 Japan Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016

TABLE 115 Japan Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016

TABLE 116 Japan Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016

TABLE 117 Japan Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016

TABLE 118 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017

TABLE 119 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026

TABLE 120 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017

TABLE 121 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026

TABLE 122 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017

TABLE 123 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026

TABLE 124 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017

TABLE 125 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026

TABLE 126 APEJ Current Expenditure on Health, (% of GDP), by Country, 2010 - 2016

TABLE 127 APEJ Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016

TABLE 128 APEJ Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016

TABLE 129 APEJ Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016

TABLE 130 APEJ Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016

TABLE 131 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017

TABLE 132 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026

TABLE 133 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017

TABLE 134 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026

TABLE 135 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017

TABLE 136 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026

TABLE 137 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017

TABLE 138 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026

TABLE 139 MEA Current Expenditure on Health, (% of GDP), by Country, 2010 - 2016

TABLE 140 MEA Per Capita Health Expenditure (US$ PPP), by Country, 2010 - 2016

TABLE 141 MEA Per Capita Healthcare Expenditure Y-o-Y Growth (in Real terms %), by Country, 2010 - 2016

TABLE 142 MEA Out-of-Pocket Healthcare Expenditure, % of Healthcare Expenditure, by Country, 2010 - 2016

TABLE 143 MEA Per Capita Healthcare Expenditure (at Current Price, in US$), by Country, 2010 - 2016

TABLE 144 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017

TABLE 145 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026

TABLE 146 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017

TABLE 147 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026

TABLE 148 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017

TABLE 149 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026

TABLE 150 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017

TABLE 151 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026

List of Figures

FIG. 1 Global Immune Checkpoint Inhibitors Market Value (US$ Mn), 2012-2017

FIG. 2 Global Immune Checkpoint Inhibitors Market Value (US$ Mn) Forecast, 2018-2026

FIG. 3 Global Immune Checkpoint Inhibitors Market Value (US$ Mn) and Y-o-Y, 2017-2026

FIG. 4 Global PD-1 Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 5 Global PD-1 Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 6 Global PD-1 Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 7 Global PD-L1 Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 8 Global PD-L1 Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 9 Global PD-L1 Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 10 Global CTLA-4 Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 11 Global CTLA-4 Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 12 Global CTLA-4 Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 13 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 14 Global Hospital Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 15 Global Hospital Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 16 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 17 Global Retail Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 18 Global Retail Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 19 Global Specialty Pharmacies Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 20 Global Specialty Pharmacies Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 21 Global Specialty Pharmacies Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 22 Global Melanoma Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 23 Global Melanoma Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 24 Global Melanoma Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 25 Global Lung Cancer Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 26 Global Lung Cancer Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 27 Global Lung Cancer Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 28 Global Blood Cancers Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 29 Global Blood Cancers Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 30 Global Blood Cancers Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 31 Global Renal Cell Carcinoma Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 32 Global Renal Cell Carcinoma Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 33 Global Renal Cell Carcinoma Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 34 Global Squamous Cell Carcinoma Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 35 Global Squamous Cell Carcinoma Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 36 Global Squamous Cell Carcinoma Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 37 Global Urothelial Carcinoma Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 38 Global Urothelial Carcinoma Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 39 Global Urothelial Carcinoma Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 40 Global Colorectal Cancer Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 41 Global Colorectal Cancer Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 42 Global Colorectal Cancer Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 43 Global Other Cancers Segment Market Value (US$ Mn) By Region, 2012-2017

FIG. 44 Global Other Cancers Segment Market Value (US$ Mn) By Region, 2018-2026

FIG. 45 Global Other Cancers Segment Y-o-Y Growth Rate, By Region, 2017-2026

FIG. 46 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017

FIG. 47 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026

FIG. 48 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017

FIG. 49 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026

FIG. 50 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017

FIG. 51 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026

FIG. 52 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017

FIG. 53 North America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026

FIG. 54 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017

FIG. 55 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026

FIG. 56 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017

FIG. 57 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026

FIG. 58 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017

FIG. 59 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026

FIG. 60 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017

FIG. 61 Latin America Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026

FIG. 62 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017

FIG. 63 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026

FIG. 64 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017

FIG. 65 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026

FIG. 66 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017

FIG. 67 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026

FIG. 68 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017

FIG. 69 Europe Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026

FIG. 70 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017

FIG. 71 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026

FIG. 72 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017

FIG. 73 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026

FIG. 74 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017

FIG. 75 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026

FIG. 76 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017

FIG. 77 Japan Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026

FIG. 78 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017

FIG. 79 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026

FIG. 80 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017

FIG. 81 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026

FIG. 82 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017

FIG. 83 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026

FIG. 84 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017

FIG. 85 APEJ Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-2026

FIG. 86 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2012-2017

FIG. 87 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Country 2018-2026

FIG. 88 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2012-2017

FIG. 89 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Drug Class 2018-2026

FIG. 90 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2012-2017

FIG. 91 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Distribution Channel 2018-2026

FIG. 92 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2012-2017

FIG. 93 MEA Immune Checkpoint Inhibitors Market Value (US$ Mn), By Therapeutic Application 2018-202

Back to Top